NURIX THERAPEUTICS, INC. (NRIX) FY2026 YTD Q3 P&L / Income Statement

NURIX THERAPEUTICS, INC. (NRIX) FY2026 YTD Q3 P&L / Income Statement

Income statement for 2025-12-01 through 2026-08-31. View: Collaborative Arrangement and Arrangement Other than Collaborative. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenue

688,359,000 US dollars

Total operating expenses

315,607,000 US dollars

Income (loss) from operations

372,752,000 US dollars

Other income (expense), net (calculated)

13,681,000 US dollars

Income (loss) before income taxes

386,433,000 US dollars

Provision for income taxes

13,335,000 US dollars

Net income (loss)

373,098,000 US dollars

Sanofi Agreement

12,000,000 US dollars

Pfizer

19,400,000 US dollars

Undisclosed (calculated)

656,959,000 US dollars

Total operating expenses

315,607,000 US dollars

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.